ATI RN
ATI Pharmacology
1. A client is prescribed gentamicin for an infection. Which finding indicates a potential adverse reaction to the medication?
- A. Blood pressure 160/90 mm Hg
- B. Presence of red blood cells in the urine
- C. Urine output of 35 mL/hr
- D. Respiratory rate of 22/min
Correct answer: B
Rationale: The presence of red blood cells in the urine is a significant finding that can indicate nephrotoxicity, a potential adverse effect of gentamicin. Nephrotoxicity can lead to kidney damage, and monitoring for this adverse reaction is crucial during gentamicin therapy. Elevated blood pressure (Choice A) is not typically associated with gentamicin adverse reactions. Decreased urine output (Choice C) may suggest kidney impairment but is not as specific as the presence of red blood cells in the urine. Respiratory rate (Choice D) is not directly related to potential adverse reactions to gentamicin.
2. Which of the following conditions is not treated with epinephrine?
- A. Renal disease
- B. Asthma
- C. Hypotension
- D. Glaucoma
Correct answer: A
Rationale: Epinephrine is not used to treat renal disease. Epinephrine is commonly used to treat conditions like asthma, hypotension, and glaucoma, but it is not an appropriate treatment for renal disease. Renal disease requires specific management strategies that do not involve the use of epinephrine.
3. A client asks the nurse how Rituximab works, which the client is receiving to treat Non-Hodgkin's Leukemia. Which of the following should the nurse include?
- A. Blocks hormone receptors
- B. Increases immune response
- C. Binds with specific antigens on tumor cells
- D. Stops DNA replication during cell division
Correct answer: C
Rationale: Rituximab is a monoclonal antibody that binds with specific antigens on B-lymphocytes, leading to the destruction of cancer cells. In the context of Non-Hodgkin's Leukemia, Rituximab targets and destroys cancerous B-lymphocytes, which helps in treating the disease. Choices A, B, and D are incorrect. Rituximab does not block hormone receptors, increase immune response, or stop DNA replication during cell division. The primary mode of action of Rituximab is its binding with specific antigens on tumor cells, specifically B-lymphocytes, to elicit an immune response against cancerous cells.
4. A client is starting therapy with cisplatin, and a healthcare provider is providing education. Which of the following findings should the healthcare provider instruct the client to report?
- A. Tinnitus
- B. Nausea
- C. Constipation
- D. Weight gain
Correct answer: A
Rationale: The correct answer is A: Tinnitus. The healthcare provider should instruct the client to report tinnitus, as it can be an indication of ototoxicity, an adverse effect associated with cisplatin therapy. Ototoxicity is damage to the inner ear structures that can lead to hearing loss, making it crucial for the client to report any early signs such as tinnitus to prevent further complications. Choices B, C, and D are less concerning in the context of cisplatin therapy. Nausea and constipation are common side effects of cisplatin but are not typically indicative of serious complications requiring immediate reporting. Weight gain is not a typical side effect associated with cisplatin therapy and is less likely to be related to the medication.
5. What is a common side effect that typically occurs with the initial therapy of Nitroglycerine as a result of increased vasodilation?
- A. Abdominal cramps
- B. Calf pain
- C. Headache
- D. Blurred vision
Correct answer: C
Rationale: Headache is a common side effect associated with the initial therapy of Nitroglycerine due to its vasodilatory properties. The vasodilation caused by Nitroglycerine leads to relaxation of blood vessels, including those in the head, which can result in headaches. This side effect is considered normal and is often transient, diminishing with continued use of the medication.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access